
## RealRate

### PHARMACEUTICAL 2020

## LIXTE BIOTECHNOLOGY HOLDINGS INC.

Rank 298 of 362



# RealRate

### PHARMACEUTICAL 2020

## LIXTE BIOTECHNOLOGY HOLDINGS INC.

Rank 298 of 362

The relative strengths and weaknesses of LIXTE BIOTECHNOLOGY HOLDINGS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of LIXTE BIOTECHNOLOGY HOLDINGS INC. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 215% points. The greatest weakness of LIXTE BIOTECHNOLOGY HOLDINGS INC. is the variable Net Income, reducing the Economic Capital Ratio by 317% points.

The company's Economic Capital Ratio, given in the ranking table, is -497%, being 194% points below the market average of -303%.

| Input Variable                              | Value in 1000 USD |
|---|-------------------|
| Assets, Current                             | 2,672             |
| Cost of Goods Sold                          | 0                 |
| Intangible Assets                           | 0                 |
| Liabilities, Current                        | 238               |
| Liabilities, Non-Current                    | 0                 |
| Other Assets                                | 0                 |
| Other Compr. Net Income                     | 0                 |
| Other Expenses                              | 0                 |
| Other Liabilities                           | 0                 |
| Other Net Income                            | 50                |
| Property and Equipment                      | 0                 |
| Research and Development                    | 821               |
| Revenues                                    | 0                 |
| Selling, General and Administrative Expense | 1,669             |

| Output Variable          | Value in 1000 USD |
|--------------------------|-------------------|
| Assets                   | 2,672             |
| Liabilities              | 238               |
| Expenses                 | 2,490             |
| Stockholders Equity      | 2,434             |
| Net Income               | -2,440            |
| Comprehensive Net Income | -2,440            |
| Economic Capital Ratio   | -497%             |